- Halozyme (HALO) and Eisa (OTCPK:ESALF), (OTCPK:ESALY) sign a collaboration agreement for the development of Eribulin in combination with PEGPH20 for women with first line HER2-negative metastatic breast cancer.
- Eisa's Eribulin is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. It is a modified and synthetically produced analog of halichondrin B, and is believed to work by inhibition of the growth phase of microtubule dynamics which prevents cell division. Eribulin is indicated for patients with metastatic breast cancer who have received at least two chemotherapeutic regimes.
- Halozyme's PEGPH20 is an investigational drug administered intravenously that targets degradation of hyaluronan, a chain of natural sugars throughout the body that can build up around cancer cells to inhibit other therapies. The collaborative study of Eribulin and PEGPH20 will analyze whether or not the combination can improve overall response rate in patients with high levels of hyaluronan.
- The companies will jointly share the costs of a phase 1b/2 clinical trial.